Market Overview

Rovi Announces New Partnership With Intellectual Ventures

Share:

Shares of Rovi Corporation (NASDAQ: ROVI), a digital entertainment company that focuses on content discovery, were trading lower by more than 2.5 percent on Monday despite announcing a new partnership.

Rovi announced a new partnership with Intellectual Ventures, one of the largest holders of U.S. patents. As part of the partnership, Rovi will become the exclusive partner for Intellectual Ventures and license the companies' combined patent portfolio exclusive to OTT customers.

The partnership addresses all aspects of the OTT value chain from content management and delivery, streaming technologies and consumer-facing features and functionality.

Rovi added that the alliance "builds a combined and global intellectual property (IP) offering that leads the way in the discovery and personalization of digital entertainment."

"We are extremely pleased to join forces with Intellectual Ventures. Our alliance underscores Rovi's commitment to foster innovation across the media and entertainment landscape," said Samir Armaly, executive vice president, intellectual property and licensing at Rovi. "In addition to our advanced discovery product offerings, our collaboration with Intellectual Ventures will provide OTT licensees access to an even more extensive patent portfolio, all from a single provider."

Posted-In: Patent Discovery Patents roviNews

 

Related Articles (ROVI)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Here's Why Moneygram International Surged 14%

Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial